First Patients Treated in New Robotic Arrhythmia Care Program at Overland Park Regional Medical Center
December 16 2019 - 9:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announced
today that HCA Midwest Health—the largest healthcare system in the
Kansas City region—has launched a new robotic arrhythmia care
program based at Overland Park Regional Medical Center (OPRMC).
Installation of the Stereotaxis Robotic Magnetic Navigation (RMN)
System was recently completed, and the first patients have been
successfully treated using the technology at Overland Park Regional
Medical Center. Stereotaxis’ partnership with HCA Midwest Health
brings new, leading-edge treatment options for patients who have a
cardiac arrhythmia. The addition of RMN is a key component of the
cardiology program at OPRMC and HCA Midwest Health, allowing for
patient-focused clinical and technological leadership as well as
enabling the providers and clinical team to better address a range
of complex arrhythmias that otherwise might not have been
treatable. RMN uses robotics and magnetic fields to navigate a
cardiac catheter directly from the tip. The technology consists of
two robotically controlled magnets placed next to the operating
table. During the procedure, a physician uses a computer interface
to adjust the magnetic field around the patient and precisely
direct and steer this cardiac ablation catheter in the heart. Dr.
Dhanunjaya “DJ” Lakkireddy, Medical Director, Kansas City Heart
Rhythm Institute at HCA Midwest Health and a partner of Midwest
Heart and Vascular Specialists, has been at the forefront of this
technological innovation. Dr. Lakkireddy was instrumental in
authoring the meta-analysis published in the Journal of
Interventional Cardiac Electrophysiology (September 2017). The
study emphasized the clinical value of robotics for the treatment
of arrhythmias. “The new cardiac arrhythmia labs at OPRMC were
recently opened and are currently treating patients,” said Dr.
Lakkireddy. “They represent the latest advances in the field
of electrophysiology including robotic technology that enables
improved outcomes and unparalleled safety for patients during
cardiac ablation procedures. Robotics also allows OPRMC
electrophysiologists to better address a range of complex
arrhythmias that otherwise might not have been treated, providing
hope to many patients who otherwise would have had no options for
cardiac arrhythmia. We have observed the clinical value of robotic
cardiac ablation and are excited to be providing patients
convenient access to this technology.” “As a world-renowned leader
in electrophysiology research and patient care, Dr. Lakkireddy
recognizes the significant patient, provider, and physician
benefits of RMN. Stereotaxis technology affords OPRMC increased
capabilities and a new and novel way to treat patients with cardiac
arrhythmias,” explained David Fischel, Chairman and Chief Executive
Officer of Stereotaxis. “We look forward to supporting the Kansas
City Heart Rhythm Institute and HCA Midwest Health as they improve
patient care, advance clinical science, and grow a highly
successful robotic arrhythmia care practice in Kansas City.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Over 100 issued patents support the
Stereotaxis platform. The core components of Stereotaxis’ systems
have received regulatory clearance in the United States, European
Union, Japan, Canada, China, and elsewhere. For more information,
please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements by Stereotaxis (the
Company), usually containing the words "believe”, "estimate”,
"project”, "expect" or similar expressions. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to raise additional capital on a timely basis and on terms that are
acceptable, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness, or to
obtain additional financing, in either case on acceptable terms,
continued acceptance of the Company's products in the marketplace,
the effect of global economic conditions on the ability and
willingness of customers to purchase its systems and the timing of
such purchases, competitive factors, changes resulting from
healthcare reform in the United States, including changes in
government reimbursement procedures, dependence upon third-party
vendors, timing of regulatory approvals, and other risks discussed
in the Company's periodic and other filings with the Securities and
Exchange Commission. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release. There can be
no assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or
at all because some of these purchase orders and other commitments
are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised,
modified, delayed or canceled, either by their express terms, as a
result of negotiations, or by overall project changes or
delays.
Stereotaxis Contacts:David
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Sep 2023 to Sep 2024